PMC:7600245 / 71068-71312 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T334","span":{"begin":213,"end":221},"obj":"Disease"}],"attributes":[{"id":"A334","pred":"mondo_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T728","span":{"begin":57,"end":63},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T729","span":{"begin":67,"end":68},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T730","span":{"begin":86,"end":91},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T731","span":{"begin":240,"end":242},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"}],"text":"Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T77845","span":{"begin":17,"end":30},"obj":"Chemical"},{"id":"T84072","span":{"begin":86,"end":91},"obj":"Chemical"},{"id":"T3791","span":{"begin":160,"end":163},"obj":"Chemical"}],"attributes":[{"id":"A98901","pred":"chebi_id","subj":"T77845","obj":"http://purl.obolibrary.org/obo/CHEBI_3614"},{"id":"A94345","pred":"chebi_id","subj":"T84072","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A33582","pred":"chebi_id","subj":"T3791","obj":"http://purl.obolibrary.org/obo/CHEBI_29287"}],"text":"Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T554","span":{"begin":0,"end":244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2198","span":{"begin":199,"end":207},"obj":"Species"},{"id":"2200","span":{"begin":17,"end":30},"obj":"Chemical"},{"id":"2203","span":{"begin":213,"end":221},"obj":"Disease"}],"attributes":[{"id":"A2198","pred":"tao:has_database_id","subj":"2198","obj":"Tax:9606"},{"id":"A2200","pred":"tao:has_database_id","subj":"2200","obj":"MESH:D002710"},{"id":"A2203","pred":"tao:has_database_id","subj":"2203","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48)."}